Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Rare Diseases

Assessing How Emerging Therapies Will Transform...

AL Amyloidosis is a rare disease, with around 8,500 new cases diagnosed each year in the 7MM. This disease mostly affects elderly persons median age of 64, with slight male predominance (54%). As p...

May 13, 2022

Pharma News and Updates for AstraZeneca, Supernus, and BMS
VBL Therapeutics’ VB-111 (ofranergene obadenovec); BMS’s mavacamten (Camzyos); Merck’s KEYTRUDA; AstraZeneca and Daiichi’s Enhertu; Pfizer/Biohaven’s VYDURA (rimegepant); AstraZeneca’s Ultomiris; Supernus’s Viloxazine (Qlebree); AbbVie’s Rinvoq

FDA Grants Fast Track Designation to VB-111 for Platinium-resistant Ovarian Cancer The FDA has given VBL Therapeutics’ VB-111 (ofranergene obadenovec), a targeted anticancer viral gene therapy, fast track designation for use as a viable therapeutic option in patients with platinum-resistant Ovarian Cancer. VB...

Find More
Top Most Expensive Drugs in the US Healthcare Market
Top 12 Most Expensive Drugs in the US Healthcare Market

Drug pricing is one of the hottest topics in the healthcare segment. Several arguments have been put forward by people, governments, healthcare companies, and other organizations in favor of and against expensive medicines. Some of the drugs are so expensive that they are nearly out of reach of the common people. H...

Find More
Pharma News and Updates for GSK, BriaCell, Gilead, Lilly, Merck, Halozyme
GSK Acquires Sierra Oncology; BriaCell’s Targeted Breast Cancer Immunotherapy; Merck’s Tepmetko; Gilead’s Magrolimab for MDS and AML; Eli Lilly’s Retevmo; Merck’s Pneumococcal Vaccine; FDA Approves Bevacizumab Biosimilar; Halozyme to Acquire Antares Pharma

GSK Acquires Sierra Oncology for USD 1.9 Billion GlaxoSmithKline has agreed to buy Sierra Oncology and its lead drug assets, momelotinib, for anemia caused by the blood malignancy myelofibrosis. GSK is paying USD 55 per share in cash for Sierra, a 39% premium to the company's closing share price yesterday, valui...

Find More

More Views & Analysis

Pharma News and Updates Precigen, Biogen, Cerevance, Sanofi, Clovis
Precigen’s PRGN-3006; Yescarta Approved as a First CAR T-cell Therapy for R/R LBCL; Biogen & Ionis’ BIIB078; Nobelpharma’s HYFTOR (sirolimus topical gel) 0.2%; Cerevance Parkinson’s Drug; Sanofi & Regeneron’s Dupixent; Clovis’s Rubraca for Ovarian Cancer; Immunocore Eye Cancer Cell Therapy Approval

FDA Approves Yescarta as a First CAR T-cell Therapy for Initial Treatment of R/R Large B-cell Lymphoma Until now, existing CAR-T therapies have been reserved for patients with blood cancer who have tried multiple treatments. The FDA has approved Yescarta, a CD19-directed CAR-T therapy developed by Gilead Science...

Find More

Pharma News and Updates for Sanofi ViiV Argenx Novartis UCB Kyowa
Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...

Find More

Fabry Disease Treatment Landscape
Examining the Therapeutic Advances in Fabry Disease Treatment Landscape

Fabry Disease is an inherited lysosomal storage disease caused by a nonfunctional or partially functional enzyme called alpha galactosidase A (α-Gal A). Decreased activity of α-Gal A in lysosomes results in the accumulation of enzyme substrates (Gb3 and lyso-Gb3) which cause cellular damage in tissues throughout th...

Find More

Radicava for ALS
Amyotrophic Lateral Sclerosis Treatment: The Journey of Radicava and Highlights of Riluzole Formulations

Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...

Find More

parkinsons-disease-treatment-market
Most Promising Therapies in the Parkinson’s Disease Treatment Market

Parkinson's disease (PD) is the second most prevalent neurogenerative disorder, with a growing global prevalence due to population aging. Despite increased awareness and significant research advancement, Parkinson’s disease treatment options include dopamine replacement therapy, symptomatic therapies that have sign...

Find More

What-is-the-Scope-of-Adrenal-Crisis-Therapeutic-Treatment-Market-in-the-Coming-Years
Adrenal Crisis – The Hurdles in Diagnosis and Treatment

Adrenal Crisis refers to overwhelming and life-threatening adrenal insufficiency. The most common signs of Adrenal Crisis are shocking (very low blood pressure with a loss of consciousness), dehydration, and an imbalance of sodium and potassium levels in the body. In some cases, shock is then preceded by several ot...

Find More

Wearable technology has been gaining momentum for the last few years as an effect of the fourth indu.....

Find More

Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infec.....

Find More

Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder o.....

Find More

T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....

Find More

Cancer immunotherapy which is known to reactivate weakened immune cells of cancer patients, has yiel.....

Find More

Herpes zoster oticus (HZ oticus) is a viral infection of the inner, middle, and external ear. A resu.....

Find More